Green, R
In a phase 3, double-blind, randomized, controlled trial, 2,539 adults with a body-mass index (BMI) of 30 or greater, or 27 or greater with at least one weight-related complication, were given weekly subcutaneous injections of tirzepatide (5 mg, 10 mg, or 15 mg) or a placebo for 72 weeks
Through a collaborative partnership between its medical and data science teams, Munich Re Life US has undertaken a large-scale study to further understand the potential significance of GLP-1 drugs
The cardiovascular benefits demonstrated with GLP-1 receptor agonists such as semaglutide (in the SUSTAIN-6 and SELECT trials) cannot automatically be extrapolated to retatrutide, and direct evidence is still awaited
By delivering glutathione directly into the bloodstream or muscle tissue, patients may achieve faster absorption compared to oral supplements